|
|
|
|
|
SAN DIEGO, Feb 19, 2020 - (ACN Newswire) - DNX Biopharmaceuticals, a biopharmaceutical company developing long-acting therapeutic proteins for the treatment of patients with life-long diseases and a resident of Johnson & Johnson Innovation - JLABS @ Shanghai, announced today that it has entered into a strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson*. Under terms of the agreement, the Lung Cancer Initiative has taken an exclusive license to research, develop and commercialize novel molecules from within the DNX portfolio. Financial terms of the collaboration were not disclosed.
"We are delighted to be collaborating with the Lung Cancer Initiative at Johnson & Johnson," said Rajiv Datar, Ph.D., co-founder and CEO of DNX. "We look forward to progressing DNX's novel molecules into clinical development."
"Our collaboration with the Lung Cancer Initiative at Johnson & Johnson was fostered by being an awardee of the Lung Cancer Innovation QuickFire Challenge and receiving residency at Johnson & Johnson Innovation - JLABS @ Shanghai," commented Dr. Carl Edwards III, CSO of DNX. "We are now looking forward to establishing our Asia-Pacific Research and Development capabilities in Shanghai, which will be wholly dedicated to Cancer Immunotherapy."
About DNX Biopharmaceuticals, Inc.
Founded in 2014 and headquartered in San Diego, California, USA, DNX is a biopharmaceutical company developing non-immunogenic, long-acting biologic therapies for the treatment of patients with life-long diseases linked to inflammation, autoinflammation and oncology. As an awardee of the Lung Cancer Innovation QuickFire Challenge, DNX received residency at Johnson & Johnson Innovation - JLABS @ Shanghai. At JLABS Shanghai, DNX will pursue an ongoing R&D effort that leverages its intrinsically disordered protein technologies designed to explore the tumor microenvironment, leading to the identification of novel pathways that can be targeted with molecules to substantially influence "anti-tumoral" therapeutic responses. Ongoing nonclinical efforts have identified several novel candidates that may act as "Immune Checkpoint Inhibitors" alone or in combination with existing standard of care anti-PD-1 and CTLA-4 therapies to reverse CD8+ T cell functions, all with the aim of improving clinical outcomes across the vast range of cancer conditions. For more information, please visit www.dnxbio.com.
*Johnson & Johnson Enterprise Innovation Inc. is the legal entity to the agreement.
Media Contact:
Claude Gingras, CFO
Claude.Gingras@dnxbio.com
Related Links
- J&J Announcement of the Winners of the Lung Cancer QuickFire Award
https://www.newsfilecorp.com/redirect/XmpnIyDP
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/52493
Topic: Press release summary
Source: DNX Biopharmaceuticals
Sectors: BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
Latest Press Releases
HKTDC celebrates 60th Anniversary with Forum and Cocktail Reception
June 16, 2026 22:45 HKT/SGT
|
|
|
Everest Medicines Enters into Exclusive Licensing Agreement with Dimerix for DMX-200 in Greater China, South Korea and Southeast Asia
June 16, 2026 22:45 HKT/SGT
|
|
|
Scandium International Mining Initiates an Update of Its Definitive Feasibility Study at Nyngan Scandium Project
June 16, 2026 19:59 HKT/SGT
|
|
|
Japantastics Introduces Sato Mokko to the World -- A New Chapter in Japanese Artisanal Craftsmanship 
Tuesday, June 16, 2026 5:00:00 PM
|
|
|
New Study reveals Piracy Services are Exposing Millions of Asia-Pacific Consumers to Cybercrime, Identity Theft and Fraud
June 16, 2026 16:30 HKT/SGT
|
|
|
Focus Graphite Completes Final Major ESIA Technical Study, Advancing Lac Knife Toward Permitting
June 15, 2026 17:29 HKT/SGT
|
|
|
China's Top Multispectral AI Firm Shenzhen HQVT Advances Hong Kong IPO
June 15, 2026 15:04 HKT/SGT
|
|
|
Generali reveals Redion - the new brand for the Group's leading global Care platform, which encompasses Europ Assistance and Generali Employee Benefits
June 15, 2026 13:03 HKT/SGT
|
|
|
BTN Jakarta International Marathon 2026 Draws 45,500 Runners from 52 Countries
June 14, 2026 22:00 HKT/SGT
|
|
|
Hitachi Energy expands zero-emission power portfolio with HyFlex Compact
Friday, June 12, 2026 11:06:00 PM
|
|
|
|
|
More Press release >> |
|
 |
|
 |
|
